Sanofi SA’s recent disclosure of safety problems with the world’s only approved vaccine against the viral infection dengue has complicated efforts to contain a growing global epidemic and could delay potential new vaccines, public-health experts said.
Late last year, the French pharmaceutical giant said its Dengvaxia product, first approved for sale in 2015, could in some cases worsen rather than prevent symptoms of the debilitating tropical disease. It was a frightening finding, and a setback for scientists who have spent... To Read the Full Story Subscribe Sign In